In the current study, we wished to determine if the V regions
Introduction
Autoantibodies with various specificities are frequently detectable in the sera of healthy individuals and are referred to as benign, natural, or naturally occurring. However, curiously, antibodies of the same specificity may also be associated with autoimmune disease (1, 2) . For example, virtually all sera from healthy individuals contain low concentrations of naturally occurring anti-i /I IgM anti-red blood cell (RBC) antibodies or cold agglutinins (CA)' that cause no apparent immune hemolysis. The pathogenic counterparts of these autoantibodies may cause severe immune hemolytic anemia and are generally derived from monoclonal B cell expansions that may progress to frank lymphoma (3) . The anti-i and anti-I specificities of CA are broadly defined by their differential reactivities to cord (predominantly i-expressing) vs adult (predominantly Iexpressing) RBCs. Normal adult sera contain a heterogeneous population of naturally occurring CA that almost always have anti-I specificity, although rarely small amounts of anti-i CA may also be detected. In contrast, pathogenic CA (e.g., derived from B cell lymphoma) may have either anti-I or anti-i specificity (4) .
In the current study, we have begun to investigate the relationship between naturally occurring, nonpathogenic anti-i/I CA and pathogenic anti-i/I CA derived from clonal B cell expansions. In recent years, several laboratories have demonstrated a highly restricted VH4 gene use among pathogenic CA from different individuals. The heavy chain variable gene VH4.2 1 (or a closely related gene) has been found in all pathogenic monoclonal CA studied to date, suggesting that this gene may play an important role in defining the i/I specificity (5) (6) (7) (8) (9) . Our study addressed the question whether the same restricted pattern of V gene usage by pathogenic CA might be found in naturally occurring CA. The simplest hypothesis, that the VH4.2 1 gene product is the principle determinant ofanti-i / I CA activity, would predict that this same gene would encode naturally occurring CA with similar specificity. Alternatively, naturally occurring anti-i/I CA could be encoded by VH genes other than VH4.2 1. A schematic diagram illustrating these possibilities is shown in Fig. 1 .
To evaluate the genetic diversity of naturally occurring CA, we have established EBV-transformed B cell clones secreting antibodies with anti-i/I binding specificity from two individuals without evidence of immune hemolysis. VH and VL region nucleotide sequence analyses ofthese B cell clones indicate that VH genes other than VH4.21 may encode anti-i/I specificity.
These results were subsequently correlated with additional serological analyses of anti-i/I enriched CA fractions from normal sera to further understand the relationship between natural and pathogenic, monoclonal anti-i/I CA.
Methods
Generation of monoclonal anti-i/I secreting EBV-transformed B cell lines. PBL were isolated by Ficoll-Hypaque gradient centrifugation from a healthy nonanemic individual (CM) without symptoms ofcold agglutinin disease. Serum from this individual agglutinated untreated homologous red blood cells at 40C up to a titer of 1:16 . PBL were enriched 10% before EBV transformation by panning with murine monoclonal anti-idiotypic antibodies previously described (10) . Four previous attempts to establish B Figure 1 . The relationship between naturally occurring and pathogenic anti-i/I CA. The origin of pathogenic (e.g., monoclonal) CA derived from clonal B cell expansions has been previously investigated (6, 12, 18, 25) .
pathologic CA. By Western blot analysis, the anti-idiotypic antibodies bind isolated kappa light chains, and, therefore, did not bias the selection of B lymphocytes expressing selected VH genes in these experiments. Polystyrene petri dishes were coated with a mixture of antibodies (2.0 gg/ml IV.8, 1.0 gg/ml IV.6, 1 ,ug/ml IV.2, and 1.0 Ag/ml IV.9) suspended in PBS (0.01 M Na P04 and 0.15 M NaCl, pH 7. ( 13) . After subcloning, supernatants from monoclonal cell lines grown in RPMI 1640 medium were retested for hemagglutination with both ficin-treated and untreated adult (I) and cord (i) group 0 RBC using previously established methods ( 14) . Serial compared to a dilutional control (antibody incubated with 50 Al PBS in place ofthe anti-idiotypic antibody). A decrease in the score ofhemagglutination in the presence of inhibitor is expressed as percent inhibition of hemagglutination. Sequencing and cDNA cloning of V region genes. The experimental approach for the cloning and sequencing ofthe expressed IgV genes has been previously described ( 18) . Total RNA was isolated from EBVtransformed cell lines using thiocyanate-phenol chloroform extraction techniques. First-strand cDNA synthesis from 1 gg total cellular RNA was performed with reverse transcriptase (Life Sciences, Inc., St. Petersburg, FL) and an oligonucleotide primer specific for the 4 chain constant region (C,,) ( Table I ). The cDNA was amplified by PCR with Amplitaq recombinant stable Taq polymerase (Perkin-Elmer Cetus
Corp., Norwalk, CT), the same C,, primer and 5' primers complementary to the conserved portion ofpublished leader sequences for each VH gene family (1) (2) (3) (4) (5) (6) (Table I ). The same approach was used to isolate the VL region gene sequences. The primers corresponding to K constant region (C), the joining region of the X light chain (JA), the leader sequences ofeach ofthe V, families ( 1-4) and the framework I region of V. genes (consensus primer HLFW1 A) are listed in Table I . For each clone, amplification occurred with only one of the 5' primers; e.g., corresponding to leader or framework 1 sequences. PCR amplifications were carried out using a programmable thermocycler (Coy Laboratory Products, Inc., Grasslake, MI). 30 cycles were performed with soak temperatures of94°C, 55°C, and 72°C for 1 min each followed by 9 min at 72°C. The amplified products were blunt ended using Klenow fragment DNA polymerase I (Sigma Immunochemicals), gel purified using both "-40" and "reverse" universal primers ( 19) . Oligonucleotide primers were synthesized by an oligonucleotide synthesizer (Applied Biosystems, Inc., Foster City, CA) using phosphotriester chemistry. For each clone, we sequenced three to four bacterial isolates in both directions. The obtained sequences were identical and thus confirmed homogeneity of the cell populations.
Results
Establishment ofCA-secreting B cell clones PBL from normal donor CM were exposed to EBV and seeded at 1 X 103 cells/well of 96-well microtiter plates (Corning). After 4 wk ofculture, supernatants were assayed for CA activity (20) . CA activity was detected in only 3 of60 wells with growth (identified on different plates), designated 4G, 8B, and 3C. These wells were subcloned by limiting dilution ( 13) . CA-secreting cell lines that were considered clonal based on statistical analysis were subsequently expanded. These three clones (4G, 8B, and 3C) were derived from PBL selected with the V.III-specific anti-idiotype. In contrast, two trials of PBL (donor CM) selection using the anti-idiotypic antibody 9G4 did not yield any CA-secreting cell lines. EBV-transformed splenic lymphocytes from donor SC were exposed to EBV and seeded at 100, 10, and 1 cell/well. Two wells were considered to contain clonal cell lines based on statistical analysis and were designated Sp I and Sp2. These cell lines were subcloned again at 1 cell/well, tested for CA activity, and expanded.
Southern blot analyses were performed on DNA from established clones that confirmed clonality ofthe cell lines (data not shown). Furthermore, clones 4G, 3C, and 8B from donor CM showed the same JH restriction fragment pattern using three different restriction enzymes. Subsequent sequence analyses indicated that these clones were in fact identical. Consequently, we present data from only one of the clones (4G).
Serology ofcold agglutinins secreted by B cell clones
The binding specificity of the RBC autoantibodies was determined by their differential reactivity against adult and cord test group 0 RBCs (Table II) The VH genes ofanti-I specific B cell clones ofdonor CM and SC belong to the VH3 family
The VH sequences ofclones 4G (3C and 8B) are most homologous (92%) to the published germline gene WHG26 (22) (Fig.   2 A) . However, based on the level of sequence complementarity, the VH gene WHG26 cannot reliably ascribed as the germline precursor.
The VH sequence ofclone Sp 1 was most homologous (98%) to the fetally rearranged M85/20P1 VH3 gene (23) (Fig. 2 B) .
The VL genes ofthe anti-I specific clones ofdonor CM and SC are VJ and VJII genes, respectively
The VL genes from clones 4G (3C and 8B) were shown to be most closely related (96%) to the VKIIIa germline gene Vg (24) (Fig. 3 A) . Other antibody specificities encoded by rearranged genes most closely related to the Vg germline gene include a pathologic CA with anti-Pr2 specificity (25) and rheumatoid factor protein (26) .
The VL gene expressed by clone Sp 1 was only 94% homologous to the VKI germline gene Ll 1 (27) (Fig. 3 B) and its germline precursor, therefore, remains speculative, since VKI represents a complex VL gene family.
The anti-i specific B cell clone of donor SC expresses VH4.21 and VHII genes
The expressed VH gene of clone Sp2 showed closest homology (98%) with the germline gene VH4.2 1 (8), while the expressed VL gene was 98% homologous to a rearranged VII gene (VII family) (28) (Fig. 4) .
Evidence that the expressed VH and VL genes encoding anti-I ofClone 4G are somatically diversified
The expressed VH and VL genes appeared somatically mutated when compared to known germline gene sequences. To investigate whether these genes were in fact mutated rather than derived from yet unreported germline genes, we used a PCRbased approach previously described by van Es et al. (29) . Specific oligonucleotide primer pairs were made corresponding to putative mutated regions of the CDRs and to the potential germline precursor sequences (Table I ).
In addition, we isolated the putative germline precursor VL gene Vg, from autologous granulocyte DNA ofindividual CM. A similar attempt to isolate the precursor VH3 gene was not performed because of the complexity ofthe VH3 family, which contains many homologous gene segments.
VH gene analysis. In this experiment, autologous granulocyte DNA could be amplified with primers corresponding to germline sequences but not with primers corresponding to expressed CDR2 sequences. Amplification of CM granulocyte DNA was achieved using primer pairs VH3 LEADERVH3 INTRON and VH3 LEADERVH26 cDR2, but not using primer pairs, VH3 LEADER-4GVHCDRl (Fig. 5 A) . Based on sequence homology to published VH3 germline genes, the VH3 LEADER primer may be expected to amplify all VH3 genes. In contrast, the VH3 INTRON primer was designed to amplify only VH26-like genes. These amplifications were included as positive controls and to show the presence of commonly identified VH3 gene segments. The lack of amplification using 4GVHCDI suggests that the expressed VH gene of clone 4G represents a mutated rearranged VH3 gene. Additional analysis of the expressed VH3 (Fig. 6) , thus confirming the presence of Vg in the germline repertoire of CM. Second, oligonucleotide primers were made corresponding to the putative mutated regions of CDR 1 and to the potential germline precursor Vg. As expected, primer pair VKIIILEADERv gCDR1 amplified granulocyte DNA, while the primer pair VKIIILEADER-4GVLCDR' did not (Fig. 5 B) .
Taken together, these data suggest that the expressed VL gene of clone 4G is a somatically mutated Vg gene.
We applied a binomial probability model to the pattern of mutations in this VL gene as a test for positive selection (30) . The expected fraction of replacement mutations in CDR from this VL sequence is 0.22, calculated by multiplying the relative size ofthe CDR (0.28) by the fraction ofall mutations in CDR that could result in amino acid replacements (0.79). Using the binomial probability model, we calculated that the distribution of six replacement mutations in CDR of a (corrected) total of 13 mutations had a low probability of occurring at random (P = 0.046). Positive selection of replacement mutations in CDR has been observed in murine immune responses and presumably reflects selection for enhanced antigen binding (31 (32) and homology of the Sp2 D segment ( 17 nucleotides) with Dxp4 (33) (Figs. 2 and 4) . The D region sequence of clone 4G could not be reliably aligned with any of the published D gene segments. The D segments from the natural anti-i/I secreting clones 4G, Spl, and Sp2 were compared to published pathogenic anti-i/I RBC autoantibodies (6-8). However, a common D region sequence, possibly contributing to the similar serological specificities of these autoantibodies, was not apparent.
Evaluation of clonal supernatants for expression of 9G4 idiotype
Each ofthe clonal supernatants was evaluated for expression of the 9G4 idiotype (Table III) . As expected, only one of these clones, Sp2, which expresses the VH4.21 gene, was bound by the monoclonal anti-idiotypic antibody 9G4 (OD > 1.0). These findings indicate that Sp2 expresses the 9G4 idiotype, which has previously been highly associated with pathologic anti-I/i autoantibodies of (pre)neoplastic B cell origin (6, 8) .
Evaluation ofnaturally occurring CA purifiedfrom serum for expression of9G4 idiotype Purified CA, isolated from the serum of 15 individuals without immune hemolysis (including CM and SC), were evaluated by ELISA for expression ofthe 9G4 idiotype. For each individual, both anti-i-and anti-I-enriched fractions were evaluated. The quantity of 9G4-reactive IgM content of CA fractions was assessed by establishing a standard curve correlating the IgM concentration ofa known VH4.2 1-expressing monoclonal IgM CA with 9G4 reactivity. We found that of 30 fractions tested, 7 had no 9G4 reactivity, while the remainder had relatively little 9G4 reactivity (range = 1-30%). These results are summarized in Fig. 7 . These data suggest that the majority of naturally occurring circulating CA are encoded by non-VH4.2 1 immunoglobulins.
9G4 fails to inhibit hemagglutination by naturally occurring anti-i/I CA purifiedfrom serum The 9G4 antibody is known to efficiently inhibit hemagglutination by pathogenic, monoclonal anti-i/I CA encoded by the VH4.2 1 gene. Consequently, hemagglutination inhibition curves were first established for VH4.2 1-encoded proteins VOG and CAP (6) using anti-idiotypic antibody 9G4 as the inhibitor (Fig. 8) (001< 1  C(<lI   1I   4001< II  uĨ  04  I1114-91 (a301ruI  (E-II  -0ouII  uC'   lll   I~0<11I   1-<I I0  >011u  AO0-I achieved using 2.5 ,ug/ml of9G4. Naturally occurring CA were subsequently tested at concentrations of total IgM ranging from 0.1 1 to 6.4 ,ug/ml. For 14 of 14 CA evaluated, hemagglutination was not inhibited, even using high concentrations of 9G4 (5.0-15.0 ,g/ml) (Fig. 8) . This failure to inhibit hemagglutination using anti-idiotypic antibody 9G4 supports the finding that only a small fraction of circulating naturally occurring CA expresses the 9G4 idiotype. Evaluation ofnaturally occurring CA for VH3-encoded IgM content A serologic marker that would recognize all VH3 gene products is to our knowledge, currently not available. Nevertheless, we have used modified SPA, which binds to -90% of VH3-encoded IgM through Fab-binding sites ( 17) , to evaluate the presence of VH3 IgM in the CA purified from normal serum and also to show that the absorption with modified SPA results in the abrogation of hemagglutination activity of the CA fractions.
Five CA fractions contained quantities of VH3 encoded IgM (OD range = 0.41-0.49) similar to the VH3 content of pooled normal human IgM (OD = 0.45) as defined by binding to modified SPA. In two ofthese CA fractions (including anti-I from donor CM), the modified SPA binding exceeded that of pooled IgM. The remaining CA fractions (19/24) contained modified SPA reactivity that was less than that of pooled normal IgM (OD < 0.20). The varying amount of modified SPA reactivity suggests that the IgM antibodies in these CA fractions are encoded by (a) VH genes other than VH3 (or VH4.2 I ); (b) certain germline VH3 genes that are not bound by modified SPA, or alternatively (c) VH3 genes that have lost modified SPA reactivity caused by somatic mutations ( 17) . A positive control antibody (representing 100% VH3-encoded IgM, at 0.25 ,ug/ml) gave an average OD value of 0.55. These experiments suggested that some purified CA fractions contained very high amounts of VH3-encoded IgM, which was unlikely caused by nonspecific Ig entrapment during the RBC absorption and elution procedure.
Next, we used modified SPA bound to microtiter plates to specifically absorb VH3 IgM from CA fractions and subsequently test the absorbed anti-I CA fractions for CA activity. After six sequential absorptions with SPA, three separate anti-I CA fractions (individuals CM, MS, and MG) failed to agglutinate adult (I) RBCs, whereas the unabsorbed fractions titered to 1:16, 1:16, and 1:32, respectively. This finding suggests that the anti-I binding specificity virtually completely results from VH3 IgM in these CA fractions. As expected, SPA-bound IgM (absorbed from the CA fractions) was detected in each of six wells on the microtiter plate (Table IV) . There was no absorption of IgM from the naturally occurring CA onto wells without SPA coat. There was also no absorption of a VH4.2 1-encoded IgM CA CAP onto wells with or without SPA coat. Together, these studies suggest that naturally occurring CA may be encoded by VH3 genes.
Relative 9G4 reactivity of a-i versus a-l CA fractions in normal serum 
Discussion
The Ig V region gene use of pathogenic, monoclonal CA has been extensively studied by serology, protein chemistry, and recently by nucleotide sequencing, whereas the VH and VL region structure of naturally occurring CA has not been previously determined. Because these proteins are present in sera in much smaller quantities than the monoclonal CA, they have not been amenable to purification and subsequent analyses as performed on monoclonal CA. Thus, there is little or no information reported regarding their structure or origin. While the naturally occurring CA are probably polyclonal in origin, based on analogy with other naturally occurring autoantibodies, such as anti-DNA antibodies, the polyclonality ofthese CA has not been demonstrated adequately. Furthermore, because the V gene usage ofnaturally occurring CA is not known, the B cell origin of naturally occurring vs pathogenic CA has remained speculative.
In the current study, naturally occurring anti-I autoantibodies from two individuals were found to use VH3 family genes, the largest of the VH families (34). This finding indicates that naturally occurring CA may derive from B cells that are distinct from the VH4.2 1 expressing cells, which can give rise to B cell neoplasms. The initial isolation ofVH3 encoded anti-I autoantibodies from donor CM using K chain-restricted anti-idiotypes was somewhat surprising in view of the published restricted use of VH4.2 1 or a closely related VH4 gene by pathogenic anti-i/I RBC autoantibodies (5-9). Therefore, we subsequently used the 9G4 anti-idiotypic antibody (associated with the VH4.2 1 gene) to attempt to isolate 9G4-positive autoreactive B cell clones. Although no CA-secreting clones were obtained from PBL of donor CM, we did isolate from splenic lymphocytes of donor SC one clone SpI (anti-I), which, curiously, is encoded by a VH3 family gene and another clone Sp2 (anti-i), which indeed is encoded by the VH4.21 gene. The isolation ofa clone expressing VH3 using the 9G4 reagent likely occurred because the panning procedure for B cell enrichment does not exclusively select idiotype-positive B cells, and because subsequent screening of the wells containing EBV transformed splenic B cells was based on CA activity and not on the expression of 9G4.
Interestingly, one ofthe VH3 genes encoding anti-I specificity is 98% homologous to the 20p 1 gene (23). This gene belongs to a set of VH genes associated with fetal ontogeny (e.g., VH26 related), which are considered to be preferentially expressed during fetal development and which, in germline configuration, are associated with several natural autoantibodies (35) . In certain instances, antibodies encoded by these fetally derived VH genes with few amino acid substitutions, may crossreact with both self antigens (e.g., anti-DNA) and with bacterial polysaccharides (36) . By analogy, it is possible that the few somatic changes observed in the VH3 gene expressed by clone Sp 1, may play a role in conferring the anti-I specificity. However, the comparison of VH region genes that encode both natural and pathogenic anti-i and anti-I CA has not revealed a shared protein sequence that would potentially contribute to anti-i/I antigen binding. The great majority of naturally occurring CA have the anti-I specificity, and when the anti-i specificity is present, it is usually found in smaller amounts (titers) relative to anti-I. Therefore, we anticipated that clones screened for CA activity would most likely have anti-I specificity, as did clone Spl . The isolation of clone Sp2, with anti-i specificity, from the same donor SC raised the question of the relative frequency of these two specificities. Since small numbers of independent clones were isolated and since enrichment by panning was used, it is difficult to estimate the relative frequencies of anti-I vs anti-i expressing B cells, or of VH4.2 1-encoded vs non-VH4.2 1-encoded natural occurring anti-i/I CA.
It is possible, however, to assess circulating naturally occurring CA for the relative expression of VH4.2 1-vs non-VH4.2 1-encoded IgM, as defined by 9G4 reactivity. We found that of 30 fractions tested, 7 had no 9G4 reactive IgM, while the remainder had relatively little 9G4 reactive IgM (Fig. 7) . For donor CM, from whom clone 4G (B cell clone, secreting VH3 encoded anti-I CA) was isolated, circulating anti-i and anti-I fractions contained only 4% and 0% 9G4 reactive IgM, respectively. In addition, the anti-i/I CA fractions of donor CM, as well as the remainder of anti-i/I fractions, were not inhibited by the 9G4 antibody (Fig. 8) . VH3 IgM was detected in several CA fractions and was found to be enriched in donor CM anti-I fraction compared to pooled IgM. Moreover, absorption of CA fractions with modified SPA to remove VH3-encoded Ig resulted in complete abrogation of anti-I binding specificity for each of three CA fractions evaluated (Table IV) . Together, the data suggest that to a large extent, naturally occurring anti-i/I CA are encoded by non-VH4.21 genes.
In summary, the current work represents an extension of our previously established model involving pathogenic CA derived from clonal B cell expansions (6, 12, 18, 25) to permit a comparison with nonpathogenic anti-i/I CA. The observed differences in V region gene use by naturally occurring vs pathogenic CA would suggest that natural/nonpathogenic anti-i/I autoantibodies may not necessarily represent the precursors of their monoclonal counterpart, and that perhaps the mechanisms leading to the development of the two different anti-i/I autoantibody populations may also differ. For example, the presence of the I antigen on L. monocytogenes raises the possibility that naturally occurring anti-I CA may arise from microbial stimulation, similar to naturally occurring anti-A, B, and H isoagglutinins, while pathogenic, monoclonal anti-i/I CA may primarily arise by alternative mechanisms (37, 38) .
